<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01342744</url>
  </required_header>
  <id_info>
    <org_study_id>Si091/2011</org_study_id>
    <nct_id>NCT01342744</nct_id>
  </id_info>
  <brief_title>Metformin in Postmenopausal Women With Metabolic Syndrome</brief_title>
  <official_title>Effects of Metformin on Cardiovascular Risk Factors in Postmenopausal Women With Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of metformin on cardiovascular risk
      factors in postmenopausal women with metabolic syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">March 2012</completion_date>
  <primary_completion_date type="Anticipated">March 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular risk factors</measure>
    <time_frame>6 months</time_frame>
    <description>To compare the cardiovascular risk factors, including blood pressue, fasting blood sugar (FBS), Homeostasis Model of Assessment - Insulin Resistance (HOMA-IR), 75-g oral glucose tolerance test (75-g OGTT), lipid profile, high sensitivity C-reactive protein(hs-CRP), neck circumference and waist circumference, between metformin and plcebo at 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>10-year risk of coronary heart disease</measure>
    <time_frame>6 months</time_frame>
    <description>To compare 10-year risk of coronary heart disease, which is calculated from RAMA- Electricity Generating Authority of Thailand (RAMA-EGAT) score, between metformin group and placebo at 6 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin (850mg) 1 tab oral twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 1 tab oral twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin(850 mg) 1tab oral twice aday</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 1 tab oral twice a day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women aged 45-60 years with metabolic syndrome according to The
             American Heart Association and The National Heart, Lung, and Blood Institute

        Exclusion Criteria:

          -  Previous cardiovascular diseases

          -  Contraindicated to metformin: serum creatinine &gt;1.4 mg/dL, liver disease, alcoholism,
             congestive heart failure, chronic hypoxic lung disease, prior history of lactic
             acidosis

          -  Previous administration of metformin, other hypoglycemic drugs, lipid-lowering drugs,
             sex steroids, antiplatelet drugs within 3 months before enrollment

          -  Fasting blood sugar ≥ 200 mg/dL or HbA1c &gt;8%

          -  Serum triglyceride ≥500 mg/dL

          -  Abnormal EKG
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suchada Indhavivadhana, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mahidol University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Suchada Indhavivadhana, M.D.</last_name>
    <phone>0-2419-4657</phone>
    <email>sisto@mahidol.ac.th</email>
  </overall_contact>
  <location>
    <facility>
      <name>Siriraj Hospital</name>
      <address>
        <city>Bangkoknoi</city>
        <state>Bangkok</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suchada Indhavivadhana, M.D.</last_name>
      <phone>0-2419-4657</phone>
      <email>sisto@mahidol.ac.th</email>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2011</study_first_submitted>
  <study_first_submitted_qc>April 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2011</study_first_posted>
  <last_update_submitted>May 14, 2011</last_update_submitted>
  <last_update_submitted_qc>May 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2011</last_update_posted>
  <responsible_party>
    <name_title>Suchada Indhavivadhana</name_title>
    <organization>Mahidol University</organization>
  </responsible_party>
  <keyword>Cardiovascular risk factors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

